Nobilon acquires rights to EBx cell lines from Vivalis for development, production and marketing of influenza vaccines
01-Jun-2007
The licence is world-wide and non-exclusive. The financial terms of the agreement, which remain confidential, include an upfront payment, milestone payments and royalties.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.